Subbu Nambi
Stock Analyst at Guggenheim
(2.01)
# 2,835
Out of 4,784 analysts
30
Total ratings
36.36%
Success rate
-1.84%
Average return
Main Sectors:
Stocks Rated by Subbu Nambi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCYT Veracyte | Reiterates: Buy | $45 | $30.12 | +49.40% | 2 | Feb 25, 2025 | |
| TEM Tempus AI | Reiterates: Buy | n/a | $47.83 | - | 2 | Feb 25, 2025 | |
| BRKR Bruker | Reiterates: Buy | n/a | $42.08 | - | 3 | Feb 24, 2025 | |
| GH Guardant Health | Reiterates: Buy | $56 | $43.14 | +29.81% | 5 | Feb 24, 2025 | |
| ILMN Illumina | Maintains: Buy | $170 → $150 | $80.00 | +87.50% | 2 | Feb 7, 2025 | |
| NTRA Natera | Maintains: Buy | $170 → $200 | $143.94 | +38.95% | 2 | Jan 17, 2025 | |
| NEOG Neogen | Initiates: Buy | $15 | $8.64 | +73.61% | 1 | Dec 19, 2024 | |
| GRAL GRAIL | Initiates: Neutral | n/a | $26.93 | - | 1 | Oct 17, 2024 | |
| SOPH SOPHiA GENETICS | Initiates: Buy | $6 | $3.26 | +84.05% | 1 | Jun 27, 2024 | |
| NAUT Nautilus Biotechnology | Initiates: Buy | $6 | $0.89 | +576.06% | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.16 | - | 3 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $133.41 | - | 1 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $53 | $40.36 | +31.32% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $19.94 | +25.38% | 1 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $8.88 | +159.01% | 1 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $90 | $43.66 | +106.14% | 1 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.14 | - | 1 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.43 | - | 1 | Dec 14, 2023 |
Veracyte
Feb 25, 2025
Reiterates: Buy
Price Target: $45
Current: $30.12
Upside: +49.40%
Tempus AI
Feb 25, 2025
Reiterates: Buy
Price Target: n/a
Current: $47.83
Upside: -
Bruker
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $42.08
Upside: -
Guardant Health
Feb 24, 2025
Reiterates: Buy
Price Target: $56
Current: $43.14
Upside: +29.81%
Illumina
Feb 7, 2025
Maintains: Buy
Price Target: $170 → $150
Current: $80.00
Upside: +87.50%
Natera
Jan 17, 2025
Maintains: Buy
Price Target: $170 → $200
Current: $143.94
Upside: +38.95%
Neogen
Dec 19, 2024
Initiates: Buy
Price Target: $15
Current: $8.64
Upside: +73.61%
GRAIL
Oct 17, 2024
Initiates: Neutral
Price Target: n/a
Current: $26.93
Upside: -
SOPHiA GENETICS
Jun 27, 2024
Initiates: Buy
Price Target: $6
Current: $3.26
Upside: +84.05%
Nautilus Biotechnology
Jun 27, 2024
Initiates: Buy
Price Target: $6
Current: $0.89
Upside: +576.06%
Jun 26, 2024
Downgrades: Neutral
Price Target: n/a
Current: $9.16
Upside: -
Jun 18, 2024
Initiates: Neutral
Price Target: n/a
Current: $133.41
Upside: -
Jun 5, 2024
Initiates: Buy
Price Target: $53
Current: $40.36
Upside: +31.32%
Dec 14, 2023
Initiates: Buy
Price Target: $25
Current: $19.94
Upside: +25.38%
Dec 14, 2023
Initiates: Buy
Price Target: $23
Current: $8.88
Upside: +159.01%
Dec 14, 2023
Initiates: Buy
Price Target: $90
Current: $43.66
Upside: +106.14%
Dec 14, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.14
Upside: -
Dec 14, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.43
Upside: -